Navigation Links
Tigermed Sets Up Subsidiary, Hunan Tigermed Xiangya Drug R&D Ltd (Tigermed Xiangya)
Date:12/1/2008

HANGZHOU, China, Dec. 1 /PRNewswire-Asia/ -- Tigermed Consulting Co., Ltd, a leading Contract Research Organization (CRO) in China, announced that it has established a subsidiary, Hunan Tigermed Xiangya Drug R&D Ltd, with Central South University (CSU). The establishment of Tigermed Xiangya marks Tigermed's participation in the construction of a nationwide first-rate Phase I Clinical Laboratory, and further substantiates Tigermed's service ability in drug pre-clinical studies and pharmaceutical analysis. This new cooperation allows Tigermed to provide more extensive and comprehensive outsourcing clinical services for Multinational Pharmaceutical Corporations and Local Research Institutions in the research and development of innovative drugs.

Tigermed, staffed with a team of 100 plus professionals, is dedicated to providing such all-round services as Phase I-IV clinical trials, data management & statistical analysis and regulatory affairs, and Tigermed has accumulated outstanding experience in the clinical trials of innovative drugs. In July 2008, financed by Qiming Ventures, an internationally renowned venture capital organization, Tigermed entered into a period of rapid expansion.

Xiangya Medical College, predecessor of Xiangya Medical School of CSU, was founded in 1914 as one of the early western medicine colleges and universities in China, and enjoyed a high reputation as "South Xiangya, North Union", widely recognizing that Xiangya Medical College in the south and Peking Union Medical College in the north of China are the most two famous medical institutions. Currently, Xiangya Medical School of CSU has three affiliated tertiary hospitals, 8 clinical colleges and 24 stable teaching bases. Phase I Clinical Laboratory of the Drug Clinical Trial Agency in the third Xiangya Hospital of CSU is one of the first groups of Laboratories passing preliminary examination.

Tigermed Xiangya has three Evaluation Centers: the Drug Clinical Evaluation Center (DCEC), Pharmaceutical Analysis Center (PAC) and Drug Pre-clinical Evaluation Center (DPEC). DCEC mainly cooperates with the third Xiangya Hospital of CSU to conduct Phase I clinical trials for new drugs, and Pharmacokinetics (PK) and Bioequiavailability (BE) studies in other stages of clinical trials. PAC is chiefly responsible for the studies related to pharmaceutical analysis. DPEC is principally in charge of PK screening of compound candidates; PK studies, Pharmacodynamics (PD) studies, quality specification studies, and manufacturing process studies during pre-clinical studies.

Professor Cheng Zeneng, Deputy Dean of the School of Pharmacy of CSU, Director of Drug Metabolism and Pharmacokinetics Research Institute, Deputy Director of Phase I Clinical Laboratory of the Drug Clinical Trial Agency in the third Xiangya Hospital of CSU, expressed, "CSU and its affiliated hospitals are equipped with high technologies and abundant resources, in complementary, Tigermed has sufficient funds and rich management expertise, so we are quite confident of building up Tigermed Xiangya as a leading Drug Clinical Evaluation Center in China."

"To set up Tigermed Xiangya is a significant move for us to complete our clinical service chain and this union of two titans will tremendously boost Tigermed's serviceability in Phase I clinical trials," comments Ms Cao Xiaochun, Vice President of Tigermed, "We are looking forward to the great future of Tigermed Xiangya, and it will be the first trial and a unique pioneering effort in China's CRO industry".

    For more information, please contact:

     Zeng Haiyan
     Tel:   +86-571-8998-6792
     Email: pr@tigermed.net

'/>"/>
SOURCE China Medicine Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. A Better Tomorrow Treatment Center Inc., Forterus Inc.s Behavioral Healthcare Subsidiary, is the First in the Nation to Offer DNA-Customized Treatment for Individuals with a Genetic Predisposition for Addictive Behavior
2. Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc.
3. Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD
4. Viragen Internationals Subsidiary, ViraNative AB, Files to Seek Bankruptcy Protection in Sweden
5. Haemonetics Announces New Subsidiary, Haemonetics Software Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... ... May 22, 2017 , ... Baltimore ... of the Maryland Biohealth community in developing and issuing recommendations to grow Maryland's ... BioHealth Innovation Hub by 2023. , The recommendations are contained ...
(Date:5/19/2017)... York (PRWEB) , ... May 19, 2017 , ... In ... in treating gait disorders, Biodex Medical Systems, Inc. announces the release of their Gait ... therapy has been joined with a biomedical system to aid in rehabilitating individuals with ...
(Date:5/18/2017)... ... ... Clinical Supplies Management (“CSM”), a Great Point Partners II (“GPP”) portfolio company, today ... doubled in size over the past six months with the acquisition of businesses in ... CSM as Chief Financial Officer. Roger has over 25 years of experience in ...
(Date:5/18/2017)... ... May 17, 2017 , ... USDM Life Sciences ... the life sciences and healthcare industries, is honored that Jay Crowley ... conference in Brussels, Belgium. , Crowley played a crucial role in the development ...
Breaking Biology Technology:
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
(Date:3/29/2017)... March 29, 2017  higi, the health IT company ... North America , today announced a Series ... acquisition of EveryMove. The new investment and acquisition accelerates ... tools to transform population health activities through the collection ... higi collects and secures data today on ...
Breaking Biology News(10 mins):